Health & Biotech
Stories by Tim Boreham
Health & Biotech
Dr Boreham’s Crucible: Will there be a sting in the Chimeric Therapeutics tale?
Health & Biotech
HealthKick Podcast: NSB brings new solutions to medicine’s most stubborn eye problems
Health & Biotech
Dr Boreham’s Crucible: Orthocell’s got some nerve… and FDA, TGA and CE approval
Health & Biotech
Dr Boreham’s Crucible: Do these mobile X-ray deals have Micro-X primed to explode?
Experts
Tim Boreham’s 21 stocks that are primed to run in 2021 – Part II
Experts
Tim Boreham’s 21 stocks that are primed to run in 2021 – Part I
Health & Biotech
Dr Boreham’s Crucible: Is Imex dancing underneath the radiology radar?
Health & Biotech
Healthkick Podcast: Neuren is cashed up, confident and charging into a phase 3 trial
Health & Biotech
Dr Boreham’s Crucible: LBT Innovations has one product – but at least it’s on the market
Health & Biotech
Dr Boreham’s Crucible: Is Telix Pharmaceuticals grand China move really a multi-billion makeover?
Health & Biotech